New England Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

New England Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-563	Closed	-$10K	–	162
2021 Q1	$10K	Sell	563 -54,863	-99%	-$987K	﹤0.01%	161
2020 Q4	$1.01M	Hold	55,426	–	–	0.02%	102
2020 Q3	$989K	Buy	55,426 +400	+0.7%	+$7.28K	0.02%	103
2020 Q2	$987K	Hold	55,026	–	–	0.02%	100
2020 Q1	$835K	Buy	55,026 +1,400	+3%	+$25.4K	0.02%	103
2019 Q4	$1.06M	Hold	53,626	–	–	0.02%	110
2019 Q3	$922K	Hold	53,626	–	–	0.02%	113
2019 Q2	$949K	Buy	53,626 +14,694	+38%	+$267K	0.02%	115
2019 Q1	$793K	Buy	+38,932	New	+$783K	0.02%	119

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

New England Asset Management's TAK Position: Q2 2021 in Review

New England Asset Management sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 563 shares — an estimated $10K sold.

New England Asset Management first reported a position in TAK in Q1 2019 and held it in 9 quarters. The position peaked at $1.06M in Q4 2019. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

New England Asset Management reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
New England Asset Management sold 563 Takeda Pharmaceutical shares in Q2 2021, an estimated $10K.
New England Asset Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 9 quarters.
New England Asset Management's Takeda Pharmaceutical position peaked at $1.06M in Q4 2019.
304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on New England Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.